Modern reproductive medicine opens up new paths to parenthood for couples with unfulfilled desire for children. Worldwide, one in six couples is affected by infertility—a medical, emotional, and societal condition that can significantly impact quality of life (1). The need for medically assisted reproduction has also increased in Switzerland. Procedures such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic diagnosis (PGD) now enable many biological obstacles to be overcome. However, with medical progress come increased ethical and social challenges—especially in a country with strict bioethical standards like Switzerland.
Applications of Reproductive Medicine
In Vitro Fertilization (IVF)
In Switzerland, IVF has been regulated since 2001 by the Federal Law on Medically Assisted Reproduction (FMedG). In this procedure, a woman’s eggs are retrieved and fertilized outside her body with her partner’s or a donor’s sperm. The fertilized eggs—called embryos—are then placed into the uterus. This method is generally applied in cases of blocked fallopian tubes, endometriosis, or unexplained infertility (2). The success rate largely depends on the woman’s age and is about 35% per embryo transfer for women under 35 in Switzerland (3). Over 7,000 IVF cycles are carried out annually in Switzerland—and the numbers are rising (4).
Intracytoplasmic Sperm Injection (ICSI)
ICSI is an advancement of IVF. With this method, a single sperm is injected directly into the egg—a procedure especially used for male infertility. This also enables fertilization in cases of extremely low sperm quality (5). In Europe, over 70% of assisted reproductive cycles now use ICSI (6).
Preimplantation Genetic Diagnosis (PGD)
PGD allows genetic screening of embryos before implantation. It is used for couples with a known risk of serious hereditary diseases. Chromosomal abnormalities or monogenic disorders can be identified in this process. In Switzerland, this procedure has been permitted under certain conditions since a 2017 referendum (7). PGD is ethically controversial, as it involves the selection of embryos.
Challenges and Ethical Aspects
Medical Risks and Psychological Burden
In addition to physical risks—such as ovarian hyperstimulation syndrome or multiple pregnancies—the psychological burden can be considerable. Many couples find the treatment emotionally challenging and report stress, anxiety, and depression (8). Psychosocial counseling is therefore increasingly recommended as an integral part of treatment.
Access and Social Equity
Legal regulations and coverage of costs differ greatly between countries. In Switzerland, IVF and ICSI treatments are generally not covered by compulsory health insurance (9). Treatments cost between 8,000 and 15,000 CHF per cycle, depending on the clinic (10). This results in social inequity, as couples with lower incomes are disadvantaged.
Ethical Questions and Societal Discourse
The selection of embryos, the handling of surplus embryos, and questions related to germline modification raise fundamental ethical concerns. Where is the line between medical assistance and human enhancement? The issue of access for single people and same-sex couples is also part of ongoing political debate.
Future Perspectives
Research into artificial gametogenesis—that is, creating eggs and sperm from skin cells or stem cells—is opening up new possibilities, for example for infertile individuals or same-sex couples (11). AI-assisted embryo selection or genome editing with CRISPR could also play a role in the future. Many of these developments, however, are still at an early stage and raise significant ethical and regulatory questions.
Conclusion
Reproductive medicine is a dynamic field that offers hope to many people. At the same time, medical, ethical, and social issues must be resolved through dialog among science, society, and politics. Responsible handling of the possibilities offered by reproductive medicine is essential to uphold autonomy, equity, and human dignity.
Sources
1. WHO (2023). Infertility – Key facts.
https://www.who.int/news-room/fact-sheets/detail/infertility
2. ESHRE (2022). ART Fact Sheet. European Society of Human Reproduction and Embryology.
3. De Geyter, C., et al. (2020). ART in Europe, 2016. Human Reproduction Open, hoaa032.
4. FOPH – Bundesamt für Gesundheit (2023). Statistik zur medizinisch unterstützten Fortpflanzung in der Schweiz.
5. Palermo, G., et al. (1992). Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet, 340(8810), 17–18.
6. Kupka, M.S., et al. (2014). Assisted reproductive technology in Europe, 2010. Human Reproduction, 29(10), 2099–2113.
7. SAMW (2020). Medizinisch unterstützte Fortpflanzung – Ethische Richtlinien. Schweizerische Akademie der Medizinischen Wissenschaften.
8. Gameiro, S., et al. (2014). Psychological and educational interventions for infertility: a systematic review. Human Reproduction Update, 20(3), 314–329.
9. Swissmom.ch (2023). Kosten einer Kinderwunschbehandlung in der Schweiz.
10. IVF-Schweiz.ch (2024). Preise für künstliche Befruchtung.
11. Sharma, A., et al. (2022). Artificial gametogenesis: progress and prospects. Nature Reviews Genetics, 23(5), 284–297
(Image: Google DeepMind / Unsplash)
